StockData
Teva Pharmaceutical Industries Ltd logo

Teva Pharmaceutical Industries Ltd (TEVA) KPIs and segments

TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30127% above fair value
$42.62+0.05 (+0.12%)

Close on Nov 17, 2026Market cap $49.66BP/E 71.0Yield –

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Teva Pharmaceutical Industries · năm tài chính kết thúc ngày 31 tháng 12

Nhìn nhanh KPI của Teva Pharmaceutical Industries: 61 chỉ số vận hành, trong đó có Consolidated Net Revenues, AUSTEDO (deutetrabenazine) — Global Revenues và AJOVY (fremanezumab) — Global Revenues, lấy từ 162 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
United States($M)9
1,7021,5342,6432,4831,7861,5361,9742,2252,1101,7252,266
AUSTEDO($M)
676559725601495396518435407282408
Generic products (including OTC and biosimilars)($M)
6606126731,1759618496751,0941,023808
Anda($M)
366392365373402380373381394
AJOVY($M)
116871057363536358424557
Other($M)
84123608101111109171115119117608
UZEDY($M)
776355435439423524159
COPAXONE($M)
6162766262546369813073
BENDEKA and TREANDA($M)
2827363540364140414652
Generic products($M)
1,0941,023808
Europe($M)6
1,2631,3401,3141,2351,2981,1941,3541,2651,2131,2721,344
Generic products (including OTC and biosimilars)($M)
1,0241,0891,0339821,0409899799739701,004
AJOVY($M)
7876756671585856525145
Respiratory Product($M)
5859655255556160576670
Other($M)
5476969181502051248194234
COPAXONE($M)
4940464450425053535757
Generic products($M)
9739701,004937
Other Activities($M)4
627584226205597579241229249225245
Distribution($M)
4133780036537300000
Sale of Goods($M)
118109137125136129154121150128153
Other($M)
95978878987685100999792
Licensing Arrangements($M)
13-111811
International Markets($M)9
550524528557495582661613593597601
Sale of Goods($M)
527476504512469553572568574566573
Generic products (including OTC and biosimilars)($M)
419386423421410468497477486477
AJOVY($M)
4933303020282124221718
Distribution($M)
2018181412111110999
AUSTEDO($M)
20199173157131214
COPAXONE($M)
86787101013141213
Licensing Arrangements($M)
78859676657
Other($M)
-3226026512722941613
Generic products($M)
477486477169
Kỳ báo cáo trước đây (báo cáo lần cuối 2023)1
Sale of Goods($M)3
3,6023,3893,6683,9073,6363,3953,4183,7253,6403,2673,255
United States($M)
1,7041,4931,7492,0631,7551,5141,4701,8221,7141,3211,344
Europe($M)
1,2531,3121,2781,2071,2751,1981,2231,2141,2031,2521,185
North America($M)
1,444
Distribution($M)3
433396384406377384413390382391403
United States($M)
0036639200402380373381394
Europe($M)
0
North America($M)
394
Other($M)2
7015710912111776346172106121252
Europe($M)
-318231613-121224239147
United States($M)
-1920121
Licensing Arrangements($M)3
373955046463652453640547
United States($M)
172152927292235232323525
Europe($M)
13101211979961113
North America($M)
526
United States($M)
1,7021,5342,6432,4831,7861,5361,9742,2252,1101,7252,266
Europe($M)
1,2631,3401,3141,2351,2981,1941,3541,2651,2131,2721,344
Kỳ báo cáo trước đây (báo cáo lần cuối 2023)1
Corporate Segment($M)
3919721,5581,3341,1369441,1481,2301,0438901,544
Europe($M)
367401307303364329438373342423461
International Markets($M)
99657095749714110973117109
Other Segments($M)
-16-16-26-40-3219-161222
United States($M)
-765071,181937699518569748629350973
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)2
United States($M)
1,2031,0381,8231,4871,2121,0131,0971,2651,167858
Europe($M)
704734708665717658794698677738783
International Markets($M)
284244247277244278346306286297189
Kỳ báo cáo trước đây (báo cáo lần cuối 2023)1
Consolidated Net Revenues($M)3
4,3954,1423,9821,5004,4804,1763,8914,2294,3324,1643,8194,457
Consolidated Revenues — Reported YoY Change(%)
-2.0%-1.0%2.0%11.0%3.0%2.0%13.0%7.0%4.0%15.0%
Consolidated Revenues — Local Currency YoY Change(%)
-2.0%-3.0%-3.0%9.0%1.0%5.0%15.0%11.0%5.0%14.0%
Share of Consolidated Revenues in Non-U.S. Dollar Currencies(%)
46.0%47.0%48.0%43.0%45.0%46.0%48.0%47.0%47.0%48.0%50.0%47.0%
AUSTEDO (deutetrabenazine) — Global Revenues($M)3
751696578
AUSTEDO Global Revenues — Local Currency YoY Growth(%)
21.0%40.0%41.0%
AUSTEDO — United States Segment Revenues($M)2
727676559725601495396518435407282408
AUSTEDO (U.S.) — Reported YoY Change(%)
21.0%37.0%41.0%40.0%38.0%22.0%40.0%27.0%28.0%32.0%67.0%
AUSTEDO — Legacy North America Segment Revenues (FY2016–FY2023)($M)1
408
AUSTEDO (Legacy North America) — Reported YoY Change(%)
18.0%
AUSTEDO — International Markets Segment Revenues($M)1
24201991731571312145
AUSTEDO (International Markets) — Reported YoY Change(%)
42.0%571.0%30.0%29.0%32.0%-76.0%4.0%50.0%28.0%32.0%67.0%
AJOVY (fremanezumab) — Global Revenues($M)5
269244196
AJOVY Global Revenues — Local Currency YoY Growth(%)
61.0%56.0%35.0%
AJOVY — U.S. Anti-CGRP Subcutaneous Exit Prescription Market Share (IQVIA)(%)
32.8%32.5%32.0%31.0%29.6%28.6%
AJOVY — United States Segment Revenues($M)2
138116871057363536358424557
AJOVY (U.S.) — Reported YoY Change(%)
88.0%83.0%64.0%68.0%27.0%53.0%18.0%11.0%4.0%-20.0%-3.0%
AJOVY — Legacy North America Segment Revenues (FY2018–FY2023)($M)1
62
AJOVY (Legacy North America) — Reported YoY Change(%)
17.0%
AJOVY — Europe Segment Revenues($M)2
847876756671585856525145
AJOVY (Europe) — Reported YoY Change(%)
28.0%10.0%31.0%30.0%18.0%38.0%14.0%28.0%37.0%33.0%42.0%31.0%
AJOVY (Europe) — Local Currency YoY Change(%)
29.0%7.0%17.0%28.0%
AJOVY — International Markets Segment Revenues($M)2
484933303020282124221718
AJOVY (International Markets) — Reported YoY Change(%)
61.0%146.0%20.0%40.0%23.0%-7.0%65.0%16.0%35.0%58.0%26.0%
AJOVY (International Markets) — Local Currency YoY Change(%)
61.0%141.0%15.0%
UZEDY (risperidone LAI) — United States Segment Revenues($M)1
85776355435439423524159
UZEDY (U.S.) — Reported YoY Change(%)
96.0%43.0%62.0%28.0%24.0%120.0%156.0%
U.S. Generic Prescriptions Dispensed — Trailing Twelve Months (IQVIA)(M)1
2272372462542612662736829230331478
U.S. Generic Prescription Market Share (IQVIA)(%)
5.8%6.1%6.3%6.5%6.7%6.9%7.1%6.9%7.6%8.4%8.2%8.0%
Generic Products (incl. Biosimilars & OTC) — United States Segment Revenues($M)2
7186606126731,1759618496751,0941,023808667
U.S. Generic Products — Reported YoY Change(%)
39.0%-31.0%-28.0%7.0%-6.0%5.0%1.0%30.0%16.0%8.0%
Generic Products — Legacy North America Segment Revenues (FY2016–FY2023)($M)1
753
Legacy North America Generic Products — Reported YoY Change(%)
-8.0%
Generic Products (incl. OTC & Biosimilars) — Europe Segment Revenues($M)1
1,0331,0241,0891,0339821,0409899799739701,004937
Europe Generic Products — Reported YoY Change(%)
5.0%-2.0%10.0%5.0%1.0%7.0%-1.0%4.0%10.0%7.0%8.0%3.0%
Generic Products (incl. OTC & Biosimilars) — International Markets Segment Revenues($M)1
407419386423421410468497477486477507
International Markets Generic Products — Reported YoY Change(%)
3.0%2.0%-18.0%-15.0%-12.0%-16.0%-2.0%-2.0%1.0%2.0%8.0%2.0%
COPAXONE (glatiramer acetate) — United States Segment Revenues($M)4
586162766262546369813073
COPAXONE (U.S.) — Reported YoY Change(%)
8.0%-2.0%16.0%22.0%-9.0%-23.0%79.0%-13.0%-30.0%44.0%-58.0%
COPAXONE — Legacy North America Segment Revenues (FY2016–FY2023)($M)1
78
COPAXONE (Legacy North America) — Reported YoY Change(%)
24.0%
COPAXONE — Europe Segment Revenues($M)2
384940464450425053535757
COPAXONE (Europe) — Reported YoY Change(%)
12.0%-2.0%-4.0%-9.0%-18.0%-6.0%-27.0%-11.0%-5.0%-11.0%-4.0%8.0%
COPAXONE (Europe) — Local Currency YoY Change(%)
-11.0%-5.0%-14.0%-17.0%-23.0%-11.0%-24.0%-11.0%-5.0%-9.0%
COPAXONE — International Markets Segment Revenues($M)1
886787101013141213
COPAXONE (International Markets) — Reported YoY Change(%)
8.0%7.0%-43.0%-31.0%-40.0%-50.0%-11.0%-25.0%-18.0%-20.0%-32.0%
BENDEKA and TREANDA (bendamustine) — United States Segment Revenues($M)2
302827363540364140414652
BENDEKA and TREANDA (U.S.) — Reported YoY Change(%)
15.0%30.0%-26.0%-13.0%-3.0%-20.0%-21.0%-28.0%-39.0%26.0%
BENDEKA and TREANDA — Legacy North America Segment Revenues (FY2016–FY2023)($M)1
53
BENDEKA and TREANDA (Legacy North America) — Reported YoY Change(%)
-29.0%
Respiratory Products — Europe Segment Revenues($M)2
545859655255556160576670
Respiratory Products (Europe) — Reported YoY Change(%)
3.0%6.0%8.0%6.0%-13.0%-3.0%-18.0%-13.0%-1.0%-14.0%-3.0%7.0%
Respiratory Products (Europe) — Local Currency YoY Change(%)
4.0%3.0%-2.0%-2.0%-18.0%-8.0%-16.0%-13.0%-3.0%-13.0%
U.S. Generic Pipeline — Product Applications (ANDAs) Awaiting FDA Approval5
96101112116123128130127125126130137
U.S. Generic Tentative FDA Approvals (Included in Pending ANDAs)
565965666869686562606163
U.S. First-to-File (Paragraph IV) Pending Generic Products
454853545555565455565962
U.S. First-to-File Generic Products (Including Final Approvals Pending Launch)
737176778081848285858688
Share of Pending U.S. ANDAs Challenging Brand Patents (Paragraph IV)(%)
79.0%80.0%81.0%80.0%74.0%74.0%75.0%78.0%79.0%79.0%78.0%78.0%
Annual U.S. Branded Market Value of Pending ANDAs (IQVIA)
93.00102.00128.00124.00123.00128.00124.00122.00119.00112.00111.00107.00
Europe Generic Pipeline — Pending Marketing Authorization Applications (MAAs)6
1,3291,4261,4081,5481,4901,5081,5081,4231,470
Europe Countries with Pending Generic MAAs
373737373737373737
Europe Pending Generic MAAs — Distinct Compounds
10099949597939498101
Europe Pending Generic MAAs — Formulations
221225215216215219215212223
Europe Generic Marketing Approvals Received (Cumulative YTD / Full Year)
35826789622496273128686412280132442
Europe Generic Approvals Received — Distinct Compounds
433319614230167153442567
Europe Generic Approvals Received — Formulations
9574471258767351491088147124
Contingent Consideration Liabilities — Fair Value Balance (R&D & Acquisition Milestones)($M)1
43494051198303394401552656567517
Change in Fair Value of Contingent Consideration($M)
21758161911-23419279408
United States Segment — Total Revenues($M)13
1,8701,7021,5343,7732,0901,7861,5361,9742,2252,1101,7252,266
United States Segment Other Products — Reported YoY Change(%)
13.0%-25.0%13.0%255.0%-13.0%-7.0%-7.0%-72.0%-18.0%9.0%-16.0%
United States Segment — Cost of Sales($M)
4674994961,826645574523877960943867822
United States Segment — Cost of Sales (% of Segment Revenues)(%)
25.0%29.3%32.3%31.0%40.1%41.9%44.6%44.4%43.1%44.7%50.2%36.3%
United States Segment — Gross Profit Margin (% of Segment Revenues)(%)
75.0%70.7%67.7%69.0%59.9%58.1%55.4%55.6%56.9%55.3%49.8%63.7%
United States Segment — R&D Expenses($M)
196883147166161152154158151170154144
United States Segment — R&D Expenses (% of Segment Revenues)(%)
10.5%51.9%9.6%6.3%6.5%7.0%8.1%8.0%6.8%8.1%8.9%6.3%
United States Segment — S&M Expenses($M)
306294298431248250244260259270261238
United States Segment — S&M Expenses (% of Segment Revenues)(%)
16.4%17.3%19.4%12.9%11.2%13.0%14.3%13.2%11.6%12.8%15.1%10.5%
United States Segment — G&A Expenses($M)
10910790139113111951101071009389
United States Segment — G&A Expenses (% of Segment Revenues)(%)
5.9%6.3%5.9%5.1%4.6%5.2%5.0%5.5%4.8%4.7%5.4%4.0%
United States Segment — Other Operating Income / (Expense)($M)
0-5-4-30310-11-2
United States Segment — Segment Profit Margin (% of Segment Revenues)(%)
42.3%4.5%33.0%44.7%37.7%32.8%27.9%28.8%33.6%29.8%20.3%43.0%
United States Segment — Depreciation Expense($M)
393636373736
Europe Segment — Total Revenues($M)14
1,3191,2631,3401,3141,2351,2981,1941,3541,2651,2131,2721,344
Europe Segment Revenues — Reported YoY Change(%)
7.0%-3.0%12.0%-3.0%-2.0%7.0%-6.0%1.0%10.0%4.0%7.0%19.0%
Europe Segment Revenues — Local Currency YoY Change(%)
7.0%-8.0%-1.0%10.0%
Europe Segment Other Products — Reported YoY Change(%)
21.0%-34.0%52.0%-53.0%-26.0%1.0%-46.0%-12.0%19.0%-10.0%6.0%443.0%
Europe Segment — Cost of Sales($M)
562559606606570581536560566536534561
Europe Segment — Cost of Sales (% of Segment Revenues)(%)
42.6%44.3%45.2%46.1%46.1%44.8%44.9%41.4%44.8%44.2%42.0%41.7%
Europe Segment — Gross Profit Margin (% of Segment Revenues)(%)
57.4%55.7%54.8%53.9%53.9%55.2%55.1%58.6%55.2%55.8%58.0%58.3%
Europe Segment — R&D Expenses($M)
625245666259605655625652
Europe Segment — R&D Expenses (% of Segment Revenues)(%)
4.7%4.1%3.4%5.0%5.0%4.6%5.1%4.2%4.3%5.1%4.4%3.9%
Europe Segment — S&M Expenses($M)
211222215250225228199221203209194202
Europe Segment — S&M Expenses (% of Segment Revenues)(%)
16.0%17.6%16.0%19.0%18.2%17.5%16.7%16.3%16.0%17.2%15.2%15.1%
Europe Segment — G&A Expenses($M)
646673857566697567646567
Europe Segment — G&A Expenses (% of Segment Revenues)(%)
4.8%5.2%5.4%6.4%6.1%5.1%5.8%5.6%5.3%5.3%5.1%5.0%
Europe Segment — Segment Profit Margin (% of Segment Revenues)(%)
31.8%29.1%29.9%23.4%24.5%28.0%27.6%32.4%29.5%28.2%33.2%34.3%
Europe Segment — Depreciation Expense($M)
333333313130
International Markets Segment — Total Revenues($M)15
592550524528557495582661613593597601
International Markets Segment Revenues — Reported YoY Change(%)
6.0%11.0%-10.0%-20.0%-9.0%-17.0%-2.0%10.0%4.0%3.0%3.0%4.0%
International Markets Segment Revenues — Local Currency YoY Change(%)
4.0%7.0%-19.0%-20.0%-10.0%-16.0%5.0%17.0%18.0%22.0%17.0%22.0%
International Markets Segment — Other Products & Distribution Revenue($M)
10555796082556112786597749
International Markets Other Products — Reported YoY Change(%)
28.0%-1.0%30.0%-52.0%-4.0%-6.0%-21.0%112.0%14.0%2.0%24.0%23.0%
International Markets Segment — Cost of Sales($M)
276266280281280251304315307307300302
International Markets Segment — Cost of Sales (% of Segment Revenues)(%)
46.7%48.3%53.6%53.1%50.2%50.8%52.3%47.7%50.1%51.7%50.3%50.2%
International Markets Segment — Gross Profit Margin (% of Segment Revenues)(%)
53.3%51.7%46.4%46.9%49.8%49.2%47.7%52.3%49.9%48.3%49.7%54.3%
International Markets Segment — R&D Expenses($M)
312622282624252727302823
International Markets Segment — R&D Expenses (% of Segment Revenues)(%)
5.3%4.8%4.3%5.2%4.6%4.9%4.3%4.1%4.4%5.1%4.6%3.9%
International Markets Segment — S&M Expenses($M)
125128117122122114118137134145118134
International Markets Segment — S&M Expenses (% of Segment Revenues)(%)
21.2%23.3%22.3%23.0%21.9%23.0%20.2%20.7%21.9%24.5%19.8%21.9%
International Markets Segment — G&A Expenses($M)
343839403632394136383537
International Markets Segment — G&A Expenses (% of Segment Revenues)(%)
5.7%6.9%7.5%7.6%6.4%6.6%6.7%6.3%5.8%6.4%5.8%6.0%
International Markets Segment — Segment Profit Margin (% of Segment Revenues)(%)
21.1%18.0%12.3%13.3%17.0%14.9%16.7%21.4%17.8%12.3%19.6%23.2%
International Markets Segment — Depreciation Expense($M)
181717181817
Legacy North America Segment — Total Revenues (FY2016–FY2023)($M)11
2,365
Legacy North America Segment Revenues — Reported YoY Change(%)
18.0%
Legacy North America Other Products — Reported YoY Change(%)
347.0%
Legacy North America Segment — Gross Profit Margin (%)(%)
62.2%
Legacy North America Segment — R&D Expenses($M)
147
Legacy North America Segment — R&D Expenses (% of Segment Revenues)(%)
6.2%
Legacy North America Segment — S&M Expenses($M)
262
Legacy North America Segment — S&M Expenses (% of Segment Revenues)(%)
11.0%
Legacy North America Segment — G&A Expenses($M)
97
Legacy North America Segment — G&A Expenses (% of Segment Revenues)(%)
4.1%
Legacy North America Segment — Other Operating Income / (Expense)($M)
-2
Legacy North America Segment — Segment Profit Margin (%)(%)
40.9%
Total Reportable Segment Profit (U.S. + Europe + International Markets)($M)1
1,3363919721,5591,3251,1339581,1481,2141,0568921,545
Unallocated Amortization of Purchased Intangible Assets($M)
139139137145144148145144146146152144
Other Activities — Total Revenues (Anda, Teva API, Medis & Contract Manufacturing)($M)2
613627584-904598597579241229249225245
Other Activities Revenues — Reported YoY Change(%)
3.0%5.0%1.0%-6.0%-10.0%-7.0%-9.0%-2.0%6.0%2.0%3.0%-10.0%
Other Activities Revenues — Local Currency YoY Change(%)
3.0%5.0%-1.0%-9.0%-13.0%-9.0%-8.0%-2.0%5.0%2.0%2.0%-11.0%
Anda, Inc. — Third-Party Pharmaceutical Distribution Revenues (U.S.)($M)
401413378-1,130392365373402380373381394
Teva API (TAPI) — Active Pharmaceutical Ingredient Sales to Third Parties($M)4
115118109136125135130145130151128
Teva API Third-Party Sales — Reported YoY Change(%)
-8.0%-12.0%-17.0%-4.0%-4.0%-11.0%2.0%4.0%5.0%2.0%
Teva API Third-Party Sales — Local Currency YoY Change(%)
-8.0%-12.0%-17.0%-4.0%-4.0%-11.0%2.0%4.0%5.0%2.0%
Teva API (TAPI) Reporting Unit — Goodwill Carrying Balance($M)
000003188951,2991,313
Teva API (TAPI) Disposal Group — Total Assets Held for Sale (Q1–Q3 2025)($M)9
1,8361,7941,7941,8421,8091,8421,8141,7712697070
TAPI Disposal Group — Inventories Held for Sale($M)
56053452750651252050264716915916912
TAPI Disposal Group — Property, Plant & Equipment Held for Sale($M)
1,0871,0271,0171,0209759559309131013135
TAPI Disposal Group — Trade Accounts Receivable Held for Sale($M)
6864478691118732221231141460
TAPI Disposal Group — Goodwill Held for Sale($M)
22320720721320720720725548787830
TAPI Disposal Group — Intangible Assets Held for Sale($M)
18191929212122836760630
TAPI Disposal Group — Other Current Assets Held for Sale($M)
73598687931071079923
TAPI Disposal Group — Other Non-Current Assets Held for Sale($M)
1801841741841901982012360
TAPI Disposal Group — Total Liabilities Held for Sale($M)
29631333435432433435869821635626213
TAPI Disposal Group — Trade Accounts Payable Held for Sale($M)
2112472522612272352432837673920
Medis Out-Licensing & Contract Manufacturing — Additional Other Activities Revenues($M)1
989597
Medis Reporting Unit — Goodwill Carrying Balance($M)
292291291256232269251255265
Sales Reserves and Allowances — Total Ending Balance (Liability)($M)8
3,9553,8993,7074,1434,1344,0503,6963,6783,7853,7003,5943,535
GTN Reserve Balance — Customer Volume & Prompt-Pay Rebates($M)
1,8651,8001,6571,9542,0111,8491,6821,6741,7871,7381,6281,603
GTN Reserve Balance — Medicaid and Other U.S. Government Pricing Programs($M)
717675685701662626601561592568567540
GTN Reserve Balance — Wholesaler Chargebacks($M)
861903833937875998875936897869850859
GTN Reserve Balance — Product Returns($M)
397409428445446434412399389432433436
GTN Reserve Balance — Promotional & Other Sales Allowances($M)
1151121041061401431261081209311697
GTN Reserves Included in Accounts Receivable, Net($M)
625960637165725663706761
Total Sales Reserves & Allowances (Including AR Reserves)($M)
4,0173,9583,7674,2064,2054,1153,7683,7343,8483,7703,6613,596
Sales Reserves and Allowances — Balance Sheet Line Item($M)
3,9553,8993,7074,1434,1344,0503,6963,6783,7853,7003,5943,535
GTN Provisions Charged to Revenue — Current-Period Sales (Total)($M)7
3,5583,6533,4083,7533,5883,7003,5563,5273,3813,5423,3543,271
GTN Provisions (Current-Year Sales) — Rebates($M)
1,2321,2231,1641,3831,2261,2701,2501,2041,1111,2071,1181,047
GTN Provisions (Current-Year Sales) — Medicaid & Government Pricing($M)
330304292297267267219208197201181186
GTN Provisions (Current-Year Sales) — Wholesaler Chargebacks($M)
1,9462,0281,8491,9931,9782,0461,9882,0271,9752,0081,9421,943
GTN Provisions (Current-Year Sales) — Product Returns($M)
736565767074698545737359
GTN Provisions (Current-Year Sales) — Promotional & Other Allowances($M)
-2333384474330365414036
GTN Provisions (Current-Year Sales) — Reserves Included in AR($M)
101988810210710499961001019392
GTN Provisions (Current-Year Sales) — Grand Total (Incl. AR Reserves)($M)
3,6593,7513,4963,8553,6953,8043,6553,6233,4873,6373,4473,363
GTN Provisions Charged / (Credited) to Revenue — Prior-Year Sales Adjustments($M)7
-14-69-59-1043-55-10-8-312-49
GTN Prior-Year Adjustments — Rebates($M)
-31-18-29-88-9-37-114210-9
GTN Prior-Year Adjustments — Medicaid & Government Pricing($M)
22-46-8113219-406200
GTN Prior-Year Adjustments — Wholesaler Chargebacks($M)
41-110-1-8-20000-11-33
GTN Prior-Year Adjustments — Product Returns($M)
-11-4-8-12-22-36-11-11-6-7
GTN Prior-Year Adjustments — Other Allowances($M)
2-2-3-1-4-3-4-1-10-10
GTN Prior-Year Adjustments — Reserves Included in AR($M)
0000000000
GTN Prior-Year Adjustments — Grand Total (Incl. AR Reserves)($M)
-14-69-59-1043-55-10-8-312-49
GTN Credits, Payments & Deductions Applied Against Reserves (Total)($M)8
3,4763,3873,7633,7423,5033,4303,5233,5433,3273,4283,2773,087
GTN Credits & Payments Applied — Rebates($M)
1,1311,0561,4191,4371,0691,1391,2241,2621,0861,0971,086985
GTN Credits & Payments Applied — Medicaid & Government Pricing($M)
308269297269233275193225180205171131
GTN Credits & Payments Applied — Wholesaler Chargebacks($M)
1,9911,9581,9391,9332,1001,9272,0351,9741,9541,9881,9351,894
GTN Credits & Payments Applied — Product Returns($M)
738073655657557780626753
GTN Credits & Payments Applied — Other Allowances($M)
-27243538453216539641824
GTN Credits & Payments Applied — Reserves Included in AR($M)
98999111010111183103108978792
GTN Credits & Payments Applied — Grand Total (Incl. AR Reserves)($M)
3,5743,4863,8543,8523,6043,5413,6063,6463,4403,5203,3643,179
GTN Reserves — Foreign Currency Translation & Other Adjustments($M)
-12-5-228-58140-8139-5-3049
Accounts Receivable Securitization — Cash Proceeds / Beneficial Interest Collected($M)2
327311354282274336322340339317295421
Supplier Finance Program Obligations Outstanding (Confirmed Payment Obligations)($M)
24225725122517119618915816313199108
Allowance for Credit Losses on Trade Accounts Receivable($M)
717575818284807891959895
Adjusted EBITDA (Non-GAAP)($M)12
1,4964741,0551,6371,3941,2331,0411,2821,3271,1681,0051,660
EBITDA (GAAP Operating Income + Depreciation & Amortization)($M)
959108925601,131705763235208254541,020
Non-GAAP Gross Profit($M)
2,5802,2932,1089,6472,4752,2782,0542,3192,3272,2051,9638,470
Non-GAAP Gross Profit Margin (%)(%)
58.7%55.4%52.9%60.3%55.3%54.6%52.8%54.8%53.7%52.9%51.4%58.2%
GAAP Gross Profit (Per Non-GAAP Reconciliation Table)($M)
2,4402,1531,9722,3042,1021,8772,1482,0241,771
GAAP Gross Profit Margin (%)(%)
55.5%52.0%49.5%51.4%50.3%48.2%49.6%48.6%46.4%
Non-GAAP Operating Income($M)
1,3933759564,9051,2943759464,3291,2141,0568924,361
GAAP Operating Income / (Loss) Margin (%)(%)
16.2%-5.6%16.4%6.4%19.7%10.9%13.3%0.7%-1.2%-0.1%-5.7%
Non-GAAP Net Income Attributable to Teva($M)
1,013216213,4119107696022,860798697-1392,812
Non-GAAP Diluted Weighted Average Shares(M)
1,1831,1811,1791,1731,1641,1611,1591,1571,1551,1511,1431,137
Non-GAAP Effective Tax Rate (%)(%)
16.5%86.7%17.5%15.5%14.7%16.4%17.5%14.8%16.0%15.4%15.0%13.1%
Depreciation Expense (Per EBITDA Reconciliation)($M)
10610210211410510399119113113119120
Amortization of Purchased Intangible Assets (Per Non-GAAP Reconciliation)($M)
139139137145144148145144146146152144
Free Cash Flow (Teva Non-GAAP Definition)($M)4
4956221881,298515476107790922324321,486
Net Cash Provided by / (Used in) Operating Activities (Per FCF Table)($M)
241411-401,158369227-105575693103-1241,184
Beneficial Interest Collected in Exchange for Securitized Trade Receivables($M)
327311354282274336322340339317295421
Cash Used for Capital Investments (Per FCF Table)($M)
-120-104-168-142-136-96-127-129-148-97-124-120
Proceeds from Sale of Businesses and Long-Lived Assets($M)
4744208917438100
Net Debt (Total Debt Less Cash & Cash Equivalents)($M)8
12,63312,93812,886
Total Debt (Per Net Debt Reconciliation)($M)
16,71816,59316,62716,807
Senior Notes and Loans (Total Carrying Value)($M)
16,78616,65016,67716,85016,83617,25916,68717,82119,02318,68619,69519,889
Short-Term Debt & Current Maturities($M)
4,0384,5002,6121,820244644211,7812,5802,0943,0601,672
Cash and Cash Equivalents($M)
4,0853,6553,7413,5562,2032,1611,6973,3003,3192,2582,9913,226
Total Long-Term Debt — Estimated Fair Value($M)
16,18516,58616,45816,92916,83117,13316,35717,49618,70117,89318,83718,865
Financial Leverage Ratio (Debt to Total Debt + Equity)(%)
68.0%68.0%67.0%68.0%77.0%72.0%71.0%
Short-Term Debt Share of Total Debt (%)(%)
24.0%27.0%16.0%11.0%3.0%3.0%14.0%11.0%
Share of Total Debt Denominated in U.S. Dollars (%)(%)
60.0%57.0%57.0%57.0%57.0%55.0%63.0%61.0%58.0%59.0%60.0%60.0%
Legal Settlements and Loss Contingencies — Total Provision Balance($M)1
4,7204,8544,6804,7534,6685,0024,8774,8814,9154,7304,6694,771
Legal Settlements and Loss Contingencies Expense / (Benefit)($M)
2022307215560166861234508310634
Restructuring Liability Reserve — Ending Balance (Total)($M)8
114111118138168182576870555782
Restructuring Reserve — Employee Termination Costs($M)
10197104124154168445556495075
Restructuring Reserve — Other Restructuring Costs($M)
131414141414131314667
Restructuring Expense Recognized in Operations — Total($M)
5838252929154142221181318
Restructuring Expense — Employee Termination($M)
573722242815112201313712
Restructuring Expense — Other Costs($M)
113513228566
Restructuring Reserve — Cash Payments & Utilization (Total)($M)
55454560422925246193919
Restructuring Reserve Utilization — Employee Termination($M)
53444255422723216143213
Restructuring Reserve Utilization — Other Costs($M)
213502240576
Operating Lease Liabilities — Total Balance2
Operating Lease Right-of-Use (ROU) Assets($M)
321333335345342358363367364358364397
Operating Lease Liabilities — Non-Current($M)
266282280288283296288296295281294320
Property, Plant and Equipment, Net — Entity-Wide Geographic Breakdown($M)
3,7473,9283,9984,0804,8204,8104,6314,5815,6725,5735,6185,750
U.S. Real Personal Consumption Expenditures — Pharmaceutical and Other Medical Products (SAAR)
3,858.703,790.303,699.903,667.003,614.803,529.803,464.703,417.803,358.203,288.203,244.403,159.40
GAAP Consolidated Revenues($M)20
4,3954,1423,9821,5004,4804,1763,8914,2294,3324,1643,8194,457
GAAP Cost of Sales($M)
1,9551,9892,0112,0562,1762,0742,0142,1092,1832,1402,0482,041
GAAP Gross Profit($M)
2,4402,1531,9722,6562,3042,1021,8772,1212,1482,0241,7712,415
GAAP Research and Development (R&D) Expenses, Net($M)
297970222267256244247247240269242227
GAAP Selling and Marketing (S&M) Expenses($M)
709717696753656654622650626656608610
GAAP General and Administrative (G&A) Expenses($M)
298317304367317305297302298283278292
GAAP Amortization of Purchased Intangible Assets($M)
139139137145144148145144146146152145
GAAP Impairment of Long-Lived Intangible Assets($M)
242283264421218228618061
GAAP Impairment of Long-Lived Tangible Assets($M)
20491174115584443580695997
GAAP Other Asset Impairments, Restructuring and Other Items($M)
2641472677862232-22457-23280673442
GAAP Operating Income / (Loss)($M)
714-231652300882455519-29-51-5-218756
GAAP Financial Expenses, Net($M)
-414-224-216-220-237-252-225-218-272-241-250-249
GAAP Income / (Loss) Before Income Taxes($M)
300-45543780646203294-247-324-246-467507
GAAP Income Tax Expense / (Benefit)($M)
6612167-390214-78742869630-5241
GAAP Consolidated Net Income / (Loss) Before Attribution($M)
234-575369481434283220-275-390-874-419467
GAAP Net Income / (Loss) Attributable to Teva($M)
233-576369480433282214-217-437-846-139463
GAAP Basic EPS Attributable to Teva
0.20-0.490.320.380.250.19-0.39-0.75-0.12
GAAP Diluted EPS Attributable to Teva
0.20-0.490.310.370.240.18-0.39-0.75-0.12
GAAP Basic Weighted Average Shares(M)
1,1661,1651,1561,1471,1471,1381,1331,1331,123
GAAP Diluted Weighted Average Shares(M)
1,1831,1651,1791,1641,1611,1591,1331,1331,123
Potentially Dilutive Securities Excluded from Diluted EPS (Anti-Dilutive)(M)
17023171421
GAAP Total Assets($M)11
40,04239,85740,04040,74839,85640,13138,41539,32641,75841,33842,77343,479
GAAP Total Current Assets($M)
14,60213,76013,71013,94612,73612,62011,52812,55212,31411,63212,29712,485
GAAP Cash and Cash Equivalents($M)
4,0853,6553,7413,5562,2032,1611,6973,3003,3192,2582,9913,226
GAAP Trade Accounts Receivable, Net($M)
3,8373,4933,3933,7093,8103,5643,3843,0593,4623,7663,4563,408
GAAP Inventories, Net (Total)($M)4
3,1733,2213,1763,1793,3233,4973,2473,0073,9593,9273,9494,021
Inventories — Raw Materials($M)
7057517307457997247166719269821,014993
Inventories — Work in Process($M)
431423386364330392377353524489508500
Inventories — Finished Goods($M)
1,8751,8431,8481,9042,0272,1061,8951,7832,3142,2692,2382,346
Inventories — Materials in Transit and Payments on Account($M)
163204213166168276259199195186189183
GAAP Prepaid Expenses($M)
1,0141,0341,0701,1221,1151,0841,0181,0061,1271,0961,3361,255
GAAP Other Current Assets($M)
658563535539477472368409445517495504
GAAP Property, Plant and Equipment, Net($M)
3,7473,9283,9984,0804,8204,8104,6314,5815,6725,5735,6185,750
GAAP Identifiable Intangible Assets, Net (Total)($M)9
3,3033,4473,6093,7813,9364,1424,1894,4184,7564,8535,0565,387
Intangible Assets, Net — Product Rights and Licenses($M)
2,8863,0203,1643,3183,4663,6563,7083,9174,1734,2344,4154,707
Intangible Assets, Net — Trade Names($M)
225235244257264273269268290290300314
Intangible Assets, Net — In-Process Research and Development (IPR&D)($M)
192192201206206213212233294329341366
Intangible Assets — Gross Carrying Amount (Total)($M)
16,85916,92316,96617,11117,13917,20716,76416,71617,28717,09017,17818,930
Intangible Assets Gross — Product Rights and Licenses($M)
16,07816,14016,17416,30816,33816,39915,97315,91516,40816,18616,26117,981
Intangible Assets Gross — Trade Names($M)
589591591597595595579568586575576583
Intangible Assets — Accumulated Amortization (Total)($M)
13,55613,47613,35713,33013,20313,06512,57512,29812,53112,23712,12213,543
Intangible Assets Accumulated Amortization — Product Rights($M)
13,19213,12013,01012,99012,87212,74312,26511,99812,23511,95211,84613,274
Intangible Assets Accumulated Amortization — Trade Names($M)
364356347340331322310300296285276269
GAAP Goodwill (Total Carrying Value)($M)6
15,74215,83915,82216,00015,94515,94915,47716,00016,12416,48817,00717,177
Goodwill — United States Segment($M)
5,5425,5485,5485,5485,7325,7325,7325,7325,8135,8135,8135,813
Goodwill — Europe Segment($M)
8,5738,6288,6458,8128,7958,8068,3168,8128,5638,3238,3628,466
Goodwill — International Markets Segment($M)
1,1691,2021,1651,1661,1281,1221,1741,1661,1611,2081,2791,321
Goodwill — Other Activities (TAPI & Medis)($M)
460463465476292
Goodwill — Legacy North America Segment (FY2016–FY2024)($M)
00006,459
Goodwill — Accumulated Impairment Losses($M)
29,60029,60029,60029,60029,60029,60029,60029,60029,30028,70028,30028,300
GAAP Deferred Income Taxes (Non-Current Asset)($M)
2,0572,1622,1902,1911,6341,7811,7621,7992,0702,0001,9601,812
GAAP Other Non-Current Assets($M)
269387377405444470464462459434470470
GAAP Total Liabilities($M)13
32,05732,10031,80932,83432,60233,29732,14633,60635,37534,77435,23035,353
GAAP Total Current Liabilities($M)
15,42515,64613,53213,45611,49111,86111,15712,79613,79713,03713,79212,247
GAAP Short-Term Debt (Total)($M)
4,0384,5002,6121,820244644211,7812,5802,0943,0601,672
Short-Term Debt — Current Maturities & Bank Borrowings($M)
000232323232323232323
Short-Term Debt — Current Maturities of Senior Notes($M)
4,0384,5002,6001,79804381,758
Short-Term Debt — Current Maturities of Long-Term Loans($M)
4,0384,5002,6001,79814413981,7582,5572,0713,0371,649
GAAP Trade Accounts Payable($M)
2,5512,7212,5962,5312,3552,4982,2902,2032,3712,3662,4392,602
GAAP Employee-Related Obligations (Current)($M)
588488555739561481474624619492492611
GAAP Accrued Expenses (Current)($M)
2,9622,7382,6162,6872,9893,0952,9522,7922,9842,8402,7842,771
GAAP Other Current Liabilities($M)
1,0369871,1111,1821,1039409641,0201,2411,1911,1611,044
GAAP Total Non-Current Liabilities($M)
16,63216,45418,27719,37921,11121,43620,99020,80921,57821,73721,43823,106
GAAP Long-Term Debt — Senior Notes and Loans (Non-Current)($M)
12,68012,09214,01514,98616,76616,76316,23016,00216,40016,54716,58418,161
GAAP Deferred Income Taxes (Non-Current Liability)($M)
263289273296399440461483538553569606
GAAP Other Taxes and Long-Term Liabilities($M)
3,4223,7913,7093,8083,6643,9384,0114,0284,3444,3563,9914,019
GAAP Total Equity (Including Non-Controlling Interests)($M)10
7,9847,7578,2327,9147,2546,8346,2695,3806,3836,5637,5438,126
GAAP Teva Shareholders' Equity($M)
7,9797,7538,2287,9107,2506,8276,2625,3736,0656,3597,2787,506
GAAP Ordinary Shares Carrying Value($M)
595959585858585858585857
GAAP Additional Paid-In Capital($M)
28,30928,25628,20328,13328,03828,00327,96527,76427,86027,82927,79627,807
GAAP Retained Earnings / (Accumulated Deficit)($M)
-13,736-13,969-13,394-13,762-14,243-14,676-14,958-15,173-14,956-14,519-13,673-13,534
GAAP Accumulated Other Comprehensive Income / (Loss)($M)
-2,556-2,465-2,512-2,391-2,475-2,431-2,675-3,148-2,769-2,881-2,775-2,697
GAAP Treasury Shares Held at Cost($M)
4,0974,1284,1284,1284,1284,1284,1284,1284,1284,1284,1284,128
GAAP Non-Controlling Interests($M)
54444777319204265620
Ordinary Shares Issued at Period-End(M)
1,3001,2711,2711,3001,2531,2531,2531,2401,2401,2391,2381,227
Ordinary Shares Outstanding at Period-End(M)
1,1671,1651,1641,1501,1471,1471,1471,1341,1331,1331,1331,121
Treasury Shares Held at Period-End(M)
105106107107106106106107106106106106
GAAP Net Cash Provided by / (Used in) Operating Activities($M)9
241411-401,158369227-105575693103-1241,184
GAAP Share-Based Compensation Expense($M)
384043513438343429322828
GAAP Net Gain / (Loss) on Sale of Long-Lived Assets & Divestitures($M)
69128002-20211012
GAAP Net Cash Provided by / (Used in) Investing Activities($M)
210-491229165135236201202268178144301
GAAP Purchases of Property, Plant and Equipment (Capital Expenditures)($M)
-120-104-168-142-136-96-127-129-148-97-124-119
GAAP Net Cash Provided by / (Used in) Financing Activities($M)
6-11340-4536-1,744-6740-966-151-576
Proceeds from Exercise of Options and Employee Share Plans($M)
4613264400312106
Effect of Exchange Rate Changes on Cash and Cash Equivalents($M)
-27-5-17-10-9-545-121100-49-10468
Net Change in Cash, Cash Equivalents and Restricted Cash($M)
430-861851,35342464-1,603-181,061-733-236977
Cash, Cash Equivalents and Restricted Cash at Period-End($M)
4,0853,6553,7413,5562,2032,1611,6973,3003,3192,2582,9913,227

55 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Segment Realignment (Q1 2026): Beginning in Q1 2026, Teva realigned its former North America segment to establish a standalone United States reportable segment. Canada was moved to the International Markets segment and Anda, Inc. (Teva's U.S. distribution business) was moved to Other Activities. Comparative segment and product figures for FY2022–FY2025 and Q1 2023–Q4 2025 have been retrospectively restated; historical FY2016–FY2023 North America figures are preserved on dedicated Legacy North America rows.
  • Period-Split Derivations: Quarterly cash flow items and Gross-to-Net (GTN) sales reserve rollforward flows reported on a cumulative 6-month (Q2), 9-month (Q3), or full-year (10-K) basis are split into standalone quarters via Q2 = 6M − Q1, Q3 = 9M − 6M, and Q4 = FY − Q1 − Q2 − Q3 (or FY − 9M), marked with their exact derivation formula.
  • Currency & Units: Monetary figures are expressed in millions of U.S. dollars ($M) unless otherwise indicated ($B for branded market value of pending ANDAs and healthcare system savings; $/sh for per-share figures; actual dollars for compensation). Local-currency (LC) growth rates are presented as published by Teva in constant exchange rates.

Không hiện vì thiếu các kỳ gần đây (13)

  • Non-GAAP Operating Income Margin (%) — Discontinued or sparse quarterly disclosure (last reported in FY2026Q3; fewer than 3 consecutive quarters through FY2026Q3)
  • Syndicated Sustainability-Linked Revolving Credit Facility Capacity — Discontinued or sparse quarterly disclosure (last reported in FY2026Q3; fewer than 3 consecutive quarters through FY2026Q3)
  • Energy Intensity (kWh per USD of Revenue) — Discontinued annual disclosure (last reported in FY2022; missing FY2025 or prior year)
  • Revenue — Legacy Specialty Medicines Segment (Discontinued after FY2017 restructuring into regional segments; lacks continuity to FY2026Q3)
  • Revenue — Legacy Generic Medicines Segment (Discontinued after FY2017 restructuring into regional segments; lacks continuity to FY2026Q3)
  • Treanda / Bendeka International Markets Revenue (Discontinued separate disclosure after FY2024; lacks FY2025–FY2026Q3 continuity)
  • Europe Distribution Revenue (Separately reported only in FY2018; merged into Other Products thereafter)
  • International Markets Distribution Revenue (Separately reported only through FY2019; merged into Other Products thereafter)
  • Goodwill Currency Translation Adjustments by Segment (Quarterly rollforward table only reported in select periods; not continuous across all quarters)
  • Nationwide Opioid Settlement 5-Year Undiscounted Payment Schedule (Reported only in select 10-K/10-Q footnotes through Q2 2024)
  • 5-Year Contractual Debt Maturity Schedule (Reported only in annual 10-K footnotes through FY2024; omitted in FY2025 10-K XBRL)
  • Conflict Minerals (Form SD) — 3TG Suppliers Surveyed (Reported only in FY2022 and FY2025 Form SD filings; not continuous across FY2024–FY2025)
  • Consolidated Minus Parent-Only Subsidiary Extraction (Excluded: Teva files consolidated U.S. GAAP financial statements on Form 10-K/10-Q without parent-only standalone financial statements; Rule 5-04 Schedule I condensed parent information is omitted as restricted net assets do not exceed 25% of consolidated net assets)

Dữ liệu cập nhật 2026-11-10.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Teva Pharmaceutical Industries

See a number that looks wrong?